Lung Cancer News and Research

Latest Lung Cancer News and Research

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Boehringer Ingelheim today announced that new data will be presented from 7 abstracts for Gilotrif (afatinib) and investigational compounds, including nintedanib and BI 836845, from its oncology pipeline at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL, on May 30 – June 3, 2014.

31 May 2014

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., today announced expansion of the UltraSEEK™ technology, the first ultrasensitive somatic mutation detection technology for high-throughput and definitive interrogation of rare mutations that occur at less than 1% abundance in matched tissue, circulating plasma, and tumor samples.

31 May 2014

Researchers develop virtual platform that measures level of addiction of smokers

In Mexico, 21.7 percent of the population smokes, which is associated with 95 percent of  lung cancer cases and the development of 29 more different conditions.

31 May 2014

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

EKF and GILUPI, announce results from collaborative work using GILUPI CellCollector and EKF Molecular’s PointMan DNA Enrichment technology.

From EKF Diagnostics 30 May 2014

UT Southwestern researchers identify protein critical to the spread of deadly cancer cells

UT Southwestern Medical Center cancer researchers have identified a protein critical to the spread of deadly cancer cells and determined how it works, paving the way for potential use in diagnosis and eventually possible therapeutic drugs to halt or slow the spread of cancer.

29 May 2014

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

Biomedical engineering researchers have developed daisy-shaped, nanoscale structures that are made predominantly of anti-cancer drugs and are capable of introducing a "cocktail" of multiple drugs into cancer cells.

29 May 2014

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

MedPage Today, a property of Everyday Health, Inc. and CollabRx, Inc. announced today the introduction of a new physician resource, CancerRx,™ an IOS application designed to help oncologists and pathologists navigate the complex landscape of oncology therapeutic options.

28 May 2014

Researchers recreate human lung in miniature with volume of half cubic centimeter

What medications can be used to treat lung cancer, and how effective are they? Until now, drug companies have had to rely on animal testing to find out. But in the future, a new 3D model lung is set to achieve more precise results and ultimately minimize - or even completely replace - animal testing. From June 23-26, researchers will be presenting their new model at the BIO International Convention in San Diego, California (Germany Pavilion, Booth 4513-03).

28 May 2014

New database allows researchers to match old drugs for new diseases

There are thousands of drugs that silence many thousands of cancer-causing genetic abnormalities. Some of these drugs are in use now, but many of these drugs are sitting on shelves or could be used beyond the disease for which they were originally approved.

23 May 2014

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).

22 May 2014

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Disease progression-free survival is similar for patients with non-small-cell lung cancer and epidermal growth factor receptor mutations whether they receive erlotinib or gefitinib, show the results of a South Korean study.

21 May 2014

Bendamustine modestly efficacious but well tolerated in SCLC

Patients with relapsed or treatment-resistant small-cell lung cancer can achieve modest survival benefits with few side effects when treated with bendamustine, report US researchers.

21 May 2014

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

21 May 2014

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Genprex, Inc. announced today that it has enrolled the first patient in a clinical trial evaluating its lead product candidate Oncoprex in combination with erlotinib (Tarceva) for late-stage lung cancer patients.

21 May 2014

Research provides key insights into most aggressive form of pancreatic cancer

Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

21 May 2014

Pemetrexed plus erlotinib shows benefits in NSCLC

Pemetrexed used in combination with erlotinib may have clinical advantage over single-agent pemetrexed when used as a second-line treatment in patients with non-squamous non-small-cell lung cancer, researchers report.

20 May 2014

CTR1 may be required for successful platinum-based therapy in NSCLC

Tumours with undetectable levels of the copper transporter CTR1 have a significantly reduced response to platinum-based chemotherapy for non-small-cell lung cancer, study findings indicate.

19 May 2014

Vandetanib delays disease progression in elderly NSCLC patients

Vandetanib used in combination with gemcitabine significantly improves progression-free survival compared with gemcitabine alone when used as a first-line treatment for elderly patients with advanced non-small-cell lung cancer, Italian researchers report.

19 May 2014

SUVmax predicts outcome in advanced NSCLC

Parameters measured by positron emission tomography with integrated computed tomography at diagnosis can be used to predict outcome following concurrent chemoradiotherapy for stage III non-small-cell lung cancer, research shows.

19 May 2014

HRQoL changes predict survival in NSCLC

Changes in health-related quality of life during treatment may help predict survival in patients with advanced non-small-cell lung cancer, suggest findings from the EORTC 08975 study.

19 May 2014

Lung Cancer News and Research

Latest Lung Cancer News and Research

New data on Gilotrif and investigational compounds to be presented at 50th ASCO annual meeting

Agena Bioscience expands ultrasensitive somatic mutation detection technology

Researchers develop virtual platform that measures level of addiction of smokers

EKF, GILUPI report data on circulating tumour cell DNA enrichment, mutation detection

UT Southwestern researchers identify protein critical to the spread of deadly cancer cells

New nanoscale structures capable of introducing "cocktail" of multiple drugs into cancer cells

MedPage and CollabRx introduce CancerRx to help oncologists, pathologists

Researchers recreate human lung in miniature with volume of half cubic centimeter

New database allows researchers to match old drugs for new diseases

Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference

Erlotinib, gefitinib have similar efficacy in NSCLC patients with EGFR mutation

Bendamustine modestly efficacious but well tolerated in SCLC

Mayo Clinic study provides key insights into aggressive form of pancreatic cancer

Genprex initiates Phase II clinical trial of Oncoprex for late-stage lung cancer patients

Research provides key insights into most aggressive form of pancreatic cancer

Pemetrexed plus erlotinib shows benefits in NSCLC

CTR1 may be required for successful platinum-based therapy in NSCLC

Vandetanib delays disease progression in elderly NSCLC patients

SUVmax predicts outcome in advanced NSCLC

HRQoL changes predict survival in NSCLC

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Lung Cancer News and Research

Latest Lung Cancer News and Research

The ultimate guide to lung research tools and protocols eBook

Edoardo Fabini

Reducing polypharmacy through innovative drug formulation technologies

How innovation in dried blood spot testing is transforming neurological disease monitoring

Newsletters you may be interested in